Replimune Group, Inc. - Common Stock — Balance Sheet (NASDAQ:REPL) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 543.1 M461.19 M646.59 M487.72 M551.33 M332.39 M Total liabilities 44.37 M49.96 M91.3 M113.21 M135.49 M166.23 M Total equity 498.73 M411.23 M555.29 M374.51 M415.84 M166.16 M Total liabilities & shareholders' equities 543.1 M461.19 M646.59 M487.72 M551.33 M332.39 M Total debt ——28.65 M44.81 M46.38 M86.19 M Net debt ——28.65 M44.81 M46.38 M-182.7 M

News

3 Biotech Stocks to Watch Before Wall Street Catches On

Signs of Economic Resilience Boost Stocks

Replimune: Stock Buoyant On Third Try At RP1 Approval - FDA AdCom May Be Crucial (REPL)

Stock Indexes Supported by Strong Demand for Technology Stocks

Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing

QURE Was Just the Beginning: 5 Biotech Catalysts I'm Watching Now

Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations (BHVN)

Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End

Replimune Stock: Modeling The Coin Flip Of FDA Approval (NASDAQ:REPL)

REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug

uniQure: Why A Shifting FDA Could Change Everything For AMT-130 (NASDAQ:QURE)

Biotech Investors Are Tuning Out the MAHA Chaos